Nelda Connors - Boston Scientific Independent Director
| BSX Stock | USD 101.51 0.78 0.77% |
Director
Ms. Nelda J. Connors is Independent Director of the Company. Ms. Connors is the founder and Chief Executive Officer of Pine Grove Holdings, LLC, a privately held investment company that acquires and operates smalltomiddle market businesses primarily focused in power generation, construction equipment, advanced material and aftermarket automotive endmarkets. She served as President and Chief Executive Officer of Atkore International Inc., formerly the Electrical and Metal Products division of Tyco International, before it became a privately held company in December 2010. Prior to joining Tyco, she served as Vice President at Eaton Corporation where she held several positions in operations, continuous improvement, and general management. Prior to joining Eaton, Ms. Connors was employed in a number of executive and management capacities in the automotive industry. Her work over 25 years has involved responsibilities in the U.S., Europe, and Asia since 2009.
| Age | 55 |
| Tenure | 16 years |
| Address | 300 Boston Scientific Way, Marlborough, MA, United States, 01752-1234 |
| Phone | 508 683 4000 |
| Web | https://www.bostonscientific.com |
Boston Scientific Management Efficiency
The company has Return on Asset of 0.0504 % which means that on every $100 spent on assets, it made $0.0504 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0889 %, implying that it generated $0.0889 on every 100 dollars invested. Boston Scientific's management efficiency ratios could be used to measure how well Boston Scientific manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Boston Scientific's Return On Tangible Assets are fairly stable compared to the past year. Return On Capital Employed is likely to rise to 0.13 in 2025, whereas Return On Equity is likely to drop 0.07 in 2025. At this time, Boston Scientific's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 34.1 B in 2025, whereas Intangible Assets are likely to drop slightly above 5 B in 2025.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Craig Arnold | Medtronic PLC | 60 | |
| Michael Michelson | Zimmer Biomet Holdings | 69 | |
| Nicholas Valeriani | Edwards Lifesciences Corp | 64 | |
| Angela Fuente | Edwards Lifesciences Corp | N/A | |
| Roch Doliveux | Stryker | 64 | |
| Steven Loranger | Edwards Lifesciences Corp | 69 | |
| Michael Farrell | Zimmer Biomet Holdings | 48 | |
| Glenn Tilton | Abbott Laboratories | 72 | |
| Denise OLeary | Medtronic PLC | 62 | |
| Kendall Powell | Medtronic PLC | 66 | |
| Christopher Holland | STERIS plc | 54 | |
| Zachary CPA | Zimmer Biomet Holdings | N/A | |
| Nancy McKinstry | Abbott Laboratories | 62 | |
| Maria Hilado | Zimmer Biomet Holdings | 56 | |
| Gail Boudreaux | Zimmer Biomet Holdings | 59 | |
| Bob White | Smith Nephew SNATS | 58 | |
| Phebe Novakovic | Abbott Laboratories | 62 | |
| Michael Wood | STERIS plc | 74 | |
| Nirav Shah | STERIS plc | 47 | |
| Syed Jafry | Zimmer Biomet Holdings | 57 | |
| Leslie Heisz | Edwards Lifesciences Corp | 60 | |
Management Performance
| Return On Equity | 0.0889 | ||||
| Return On Asset | 0.0504 |
Boston Scientific Corp Leadership Team
Elected by the shareholders, the Boston Scientific's board of directors comprises two types of representatives: Boston Scientific inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Boston. The board's role is to monitor Boston Scientific's management team and ensure that shareholders' interests are well served. Boston Scientific's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Boston Scientific's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Edward Ludwig, Lead Independent Director | ||
| Donna James, Independent Director | ||
| Stephen MacMillan, Independent Director | ||
| Michael Mahoney, Chairman of the Board, President, Chief Executive Officer | ||
| Emily Woodworth, Global VP | ||
| Kevin Ballinger, Executive Vice President and Global President - Interventional Cardiology | ||
| Desiree RallsMorrison, Senior Vice President General Counsel, Corporate Secretary | ||
| Maulik Nanavaty, Senior Vice President and President - Neuromodulation | ||
| Ian Meredith, Executive Vice President Global Chief Medical Officer | ||
| David Pierce, Executive Vice President and President, MedSurg and President - Endoscopy | ||
| Ellen Zane, Independent Director | ||
| Joseph Fitzgerald, Executive Vice President, President, Interventional Cardiology | ||
| Eric Thepaut, Executive Vice President and President - Europe, Middle East and Africa | ||
| Daniel Brennan, CFO, Principal Accounting Officer and Executive VP | ||
| Nelda Connors, Independent Director | ||
| Wendy Carruthers, Executive Vice President - Human Resources | ||
| Jodi Eddy, Senior Vice President and Chief Information and Digital Officer | ||
| Miriam Osullivan, Senior Officer | ||
| Catherine Jennings, VP Interventions | ||
| John Sorenson, Senior Vice President - Manufacturing and Supply Chain | ||
| Arthur Butcher, Executive Vice President and President, Asia Pacific | ||
| Daniel CPA, Executive CFO | ||
| Edward Mackey, Executive Vice President - Global Operations | ||
| Scott Olson, Senior Vice President, President - Cardiac Rhythm Management and Diagnostics | ||
| Vance Brown, Senior Vice President General Counsel, Corporate Secretary | ||
| Charles Dockendorff, Independent Director | ||
| Mary Moynihan, Senior Officer | ||
| John Sununu, Independent Director | ||
| Jeffrey Mirviss, Executive Vice President and President - Peripheral Interventions | ||
| Yoshiaki Fujimori, Independent Director | ||
| David Wichmann, Independent Director | ||
| David Roux, Independent Director | ||
| Susan Lisa, VP, Investor Relations | ||
| Jonathan Monson, Chief Accounting Officer, Vice President Global Controller | ||
| Jeffrey MBA, Executive Interventions | ||
| Meghan Scanlon, Senior Vice President and President - Urology and Pelvic Health |
Boston Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Boston Scientific a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0889 | ||||
| Return On Asset | 0.0504 | ||||
| Profit Margin | 0.11 % | ||||
| Operating Margin | 0.17 % | ||||
| Current Valuation | 160.87 B | ||||
| Shares Outstanding | 1.48 B | ||||
| Shares Owned By Insiders | 0.19 % | ||||
| Shares Owned By Institutions | 93.36 % | ||||
| Number Of Shares Shorted | 12.87 M | ||||
| Price To Earning | 107.05 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Boston Stock Analysis
When running Boston Scientific's price analysis, check to measure Boston Scientific's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Boston Scientific is operating at the current time. Most of Boston Scientific's value examination focuses on studying past and present price action to predict the probability of Boston Scientific's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Boston Scientific's price. Additionally, you may evaluate how the addition of Boston Scientific to your portfolios can decrease your overall portfolio volatility.